Resiniferatoxin
As of the edition of 20 October 2026, Resiniferatoxin is a small molecule: stopped in 2024; acts on TRPV1.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 11, 3 stopped early
- Disease areas
- Bones, joints and muscles; Nervous system
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Resiniferatoxin.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| TRPV1 | Transient receptor potential cation channel subfamily V member 1 | Q8NER1 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 5 | 4 | 1 | 0 |
| Phase 2 | 3 | 0 | 1 | 0 |
| Phase 3 | 3 | 0 | 0 | 3 |
| All trials | 11 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Grünenthal | Lead sponsor of trials | 2016 to now |
| Sorrento Therapeutics | Lead sponsor of trials | 2017 to now |